KaydedilenlerDerginizi ekleyin

Dergiler / Journal of Health Sciences and Medicine / 2026 / Volume: 6 Issue: 1

FeNO, systemic inflammation and other risk factors for osteoporosis in COPD

Ömür Güngör(Hacettepe Üniversitesi Tıp Fakültesi)0000-0002-6524-8088
A. Füsun Kalpaklıoğlu(Kırıkkale Üniversitesi Tıp Fakültesi)0000-0002-6548-6932
Sayfa
—
Yayın Tarihi
2023-01-12
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusions: Osteoporosis was associated with low BMI, airway stenosis and high levels of hs-CRP and WBC.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: The bone is one of the tissues that is adversely affected as a result of inflammation in COPD.
📊
Temel Bulgular & Veri:Material and Method: A cross-sectional study was performed, including 50 patients with stable COPD.
💡
Sonuç & Katkı:Conclusions: Osteoporosis was associated with low BMI, airway stenosis and high levels of hs-CRP and WBC.
🔬Tür:Research Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:COPD · inflammation · osteoporosis

Abstract

Aim: The bone is one of the tissues that is adversely affected as a result of inflammation in COPD. The aim of this study is to examine the relationship between airway inflammation, systemic inflammation and osteoporosis in COPD. Material and Method: A cross-sectional study was performed, including 50 patients with stable COPD. FeNO as a marker of airway inflammation; hs-CRP, WBC and fibrinogen as systemic inflammation markers; arterial blood gas, BMI and FEV1 were measured. To identify osteoporosis, DEXA was performed. Results: The prevalence of osteoporosis was 26%. Osteoporosis was associated with WBC and hs-CRP (OR: 1.80, 95% CI, 1.26-2.57 and OR: 2.32, 95% CI, 1.28-4.20, respectively). It was observed that the risk increased as FEV1 and BMI decreased (OR: 0.94, 95% CI, 0.89-0.98 and OR: 0.75, 95% CI, 0.61-0.91, respectively). There was no relationship between osteoporosis and FeNO and fibrinogen (OR: 1.05, 95% CI, 0.99-1.12 and OR: 1.04, 95% CI 0.98-1.09, respectively). Arterial blood gases (PaO2 and PaCO2) were not effective on osteoporosis (OR: 1.01, 95% CI, 0.95-1.05 and OR: 1.04, 95% CI, 0.90-1.19, respectively). The cut-off values of hs-CRP and WBC for osteoporosis risk were 15.9 mg/L and 11.6 ×10⁹/L, respectively. Conclusions: Osteoporosis was associated with low BMI, airway stenosis and high levels of hs-CRP and WBC.

🔖

Bu Makaleye Atıf Yap

Güngör, Ö., Kalpaklıoğlu, A. F. (2023). FeNO, systemic inflammation and other risk factors for osteoporosis in COPD. Journal of Health Sciences and Medicine, Volume: 6 Issue: 1. https://doi.org/10.32322/jhsm.1212043

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (24)

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report) 2020. (updated 2020 Nov 25); (cited 2021 December 3). Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf.
  2. Stanojkovic I, Kotur-Stevuljevic J, Spasic S, et al. Relationship between bone resorption, oxidative stress and inflammation in severe COPD exacerbation. Clin Biochem 2013; 46: 1678-82.
  3. Agusti A, Edwards LD, Rennard SI, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PloS one 2012; 7: e37483.
  4. Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013; 68: 670-6.
  5. Fröhlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes care 2000; 23: 1835-9.
  6. Agarwal R, Zaheer MS, Ahmad Z, Akhtar J. The relationship between C-reactive protein and prognostic factors in chronic obstructive pulmonary disease. Multidiscip Respir Med 2013; 8: 1-5.
  7. Agusti AGN, Villaverde JM, Togores B, Bosch M. Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 523-8.
  8. Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 1995; 152: 609-612.
  9. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: WB Saunders; 1980.
  10. Romme EA, Smeenk FW, Rutten EP, Wouters EF. Osteoporosis in chronic obstructive pulmonary disease. Expert Rev Respir Med 2013; 7: 397-410.
  11. Biskobing DM. COPD and osteoporosis. Chest.2002; 121: 609-20.
  12. Bon J, Fuhrman CR, Weissfeld JL, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med 2011; 183: 885-90.
  13. Bolton CE, Cannings-John R, Edwards PH, et al. What community measurements can be used to predict bone disease in patients with COPD? Respir Med 2007; 102: 651-7.
  14. Santus P, Rizzi M, Radovanovic D, et al. Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. Biomed Res Int 2018; 2018: 3140682.
  15. Malerba M, Radaeli A, Olivini A, et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed Res Int 2014; 2014: 271918
  16. Lacativa PG, Farias ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol 2010; 54: 123-32.
  17. Lane NE. Therapy insight: osteoporosis and osteonecrosis in systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006; 2: 562-9.
  18. Baykal H, Bulcun E. Relationship of clinical parameters and inflammation markers with pulmonary hypertension in patients with stable chronic obstructive pulmonary disease. Sağlık Bilimlerinde Değer 2022; 12: 6-14.
  19. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-85.
  20. Rittayamai N, Chuaychoo B, Sriwijitkamol A. Prevalence of osteoporosis and osteopenia in Thai COPD patients. J Med Assoc Thai 2012; 95: 1021-7.
  21. Lin CH, Chen KH, Chen CM, Chang CH, Huang TJ, Lin CH. Risk factors for osteoporosis in male patients with chronic obstructive pulmonary disease in Taiwan. PeerJ 2018; 6: e4232.
  22. Miller J, Edwards, LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107: 1376-84.
  23. Romme EA, Murchison JT, Edwards LD, et al. CT‐measured bone attenuation in patients with chronic obstructive pulmonary disease: Relation to clinical features and outcomes. J Bone Miner Res 2013; 28: 1369-77.
  24. Karadag F, Cildag O, Yurekli Y, Gurgey O. Should COPD patients be routinely evaluated for bone mineral density? J Bone Miner Metab 2003; 21: 242-6.